Goodwill and Other Intangible Assets, Net (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Movements in Goodwill

Movements in goodwill attributable to each reportable segment for the nine months ended September 30, 2023 were as follows:

(DOLLARS IN MILLIONS)	Nourish		Health & Biosciences		Scent		Pharma Solutions		Total
Balance at December 31, 2022	$	6,050	$	4,321	$	1,745	$	1,239	$	13,355
Transferred to assets held for sale	—		—		(267)		—		(267)
Reduction from business divestitures	(4)		—		—		—		(4)
Foreign exchange	(41)		(7)		(2)		(3)		(53)
Balance at September 30, 2023	$	6,005	$	4,314	$	1,476	$	1,236	$	13,031

The goodwill balances at September 30, 2023 and December 31, 2022 include $2.250 billion of accumulated impairment related to the Health & Biosciences reportable segment. The accumulated impairment relates entirely to an impairment charge recorded in 2022.

Impairment of Goodwill

For the third quarter of 2022, the Company determined that goodwill impairment triggering events occurred for its Nourish, Health & Biosciences and Pharma Solutions reporting units, which required it to complete an interim impairment assessment. The primary indicators that were deemed to be triggering events in the quarter for the reporting units were declines in the Company’s projections across various reporting units and ongoing adverse macroeconomic impacts such as inflation, increases in interest rates and unfavorable effects from exchange rates.

As a result of the triggering events, the Company assessed the fair value of the reporting units using the income approach. Under the income approach, the Company determined the fair value by using a discounted cash flow method at a rate of return that reflected the relative risk of the projected future cash flows of each reporting unit, as well as a terminal value. The Company used the most current actual and forecasted operating data available. Key estimates and assumptions used in these valuations included revenue growth rates, gross margins, EBITDA margins, terminal growth rates and discount rates. These estimates and assumptions were considered Level 3 inputs under the fair value hierarchy.

In performing the quantitative impairment test, the Company determined that the fair value of the Nourish and Pharma Solutions reporting units exceeded their carrying value, and determined that there was no impairment of goodwill relating to these reporting units. The Company determined that the carrying value of the Health & Biosciences reporting unit exceeded its fair value and recorded a goodwill impairment charge of $2.250 billion on the Consolidated Statements of Income (Loss) and Comprehensive Loss for the three and nine months ended September 30, 2022.

Schedule of Other Intangible Assets, Net

Other intangible assets, net consisted of the following amounts:

	September 30,		December 31,
(DOLLARS IN MILLIONS)	2023		2022
Asset Type
Customer relationships	$	8,072	$	8,318
Technological know-how	2,314		2,339
Trade names & patents	331		358
Other	44		47
Total carrying value	10,761		11,062
Accumulated Amortization
Customer relationships	(1,488)		(1,252)
Technological know-how	(745)		(589)
Trade names & patents	(107)		(97)
Other	(40)		(42)
Total accumulated amortization	(2,380)		(1,980)
Other intangible assets, net	$	8,381	$	9,082

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Amortization expense for the next five years is expected to be as follows:

(DOLLARS IN MILLIONS)	2023		2024		2025		2026		2027
Estimated future intangible amortization expense	$	173	$	692	$	690	$	688	$	589